CorMedix Inc (CRMD)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Joseph Todisco
Employees:
30
1430 HIGHWAY 206, SUITE 200, BEDMINSTER, NJ 07922
908-517-9500

CorMedix Inc. focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings.

Data derived from most recent annual or quarterly report
Market Cap 140.772 Million Shares Outstanding41.282 Million Avg 30-day Volume 210.342 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.17
Price to Revenue1268.468 Debt to Equity0.0125 EBITDA-29.81 Million
Price to Book Value2.0747 Operating Margin-32588.4997 Enterprise Value58.315 Million
Current Ratio11.787 EPS Growth0 Quick Ratio11.656
1 Yr BETA 1.2547 52-week High/Low 8.03 / 2.65 Profit Margin-31794.9024
Operating Cash Flow Growth-13.4401 Altman Z-Score5.5958 Free Cash Flow to Firm -21.569 Million
Earnings Report2023-03-28
View SEC Filings from CRMD instead.

View recent insider trading info

CorMedix Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CRMD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRMD

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-20 by MISTRY ERIN
  • 3: filed on 2023-01-20 by MISTRY ERIN
  • 4: filed on 2023-01-18 by TODISCO JOSEPH
  • 4: filed on 2023-01-18 by MOUNTS PHOEBE
  • 4: filed on 2023-01-18 by LEFKOWITZ STEVEN W
  • 4: filed on 2023-01-18 by DILLIONE JANET
  • 4: filed on 2023-01-18 by KAPLAN MYRON
  • 4: filed on 2023-01-18 by MASSON-HURLBURT ELIZABETH
  • 4: filed on 2023-01-18 by DUNTON ALAN W
  • 4: filed on 2023-01-18 by DUNCAN GREGORY SCOTT

    • Events (8k)

  • 8-K: filed on 2023-03-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-21:
    Item 4.01: Changes in Registrant's Certifying Accountant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MISTRY ERIN CHIEF COMMERCIAL OFFICER

    • Officer
    		 3,900 2023-01-15 2

    DUNTON ALAN W

    • Director
    		 26,250 2023-01-14 1

    LEFKOWITZ STEVEN W

    • Director
    		 92,650 2023-01-14 1

    COSTA PAULO F

    • Director
    		 20,000 2023-01-14 1

    DILLIONE JANET

    • Director
    		 73,473 2023-01-14 1

    KAPLAN MYRON

    • Director
    		 190,034 2023-01-14 2

    MASSON-HURLBURT ELIZABETH EVP, HEAD OF CLINICAL OPS.

    • Officer
    		 133,000 2023-01-14 1

    TODISCO JOSEPH CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 642,169 2023-01-14 5

    MOUNTS PHOEBE GENERAL COUNSEL

    • Officer
    		 132,200 2023-01-14 1

    DAVID MATTHEW T CHIEF FINANCIAL OFFICER

    • Officer
    		 128,150 2023-01-14 1

    DUNCAN GREGORY SCOTT

    • Director
    		 20,000 2023-01-14 1

    NUSBICKEL THOMAS EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 367,500 2022-02-18 0

    ARMSTRONG JR. JOHN L. EXEC VP OF TECH OPERATIONS

    • Officer
    		 358,572 2021-01-11 0

    BALUCH KHOSO CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 981,135 2021-01-11 0

    KHAN MEHMOOD

    • Director
    		 216,767 2020-08-18 0

    COOK ROBERT W. CHIEF FINANCIAL OFFICER

    • Officer
    		 117,517 2019-09-30 0

    GELBFISH GARY A.

    • Director
    		 3,608,871 2019-01-10 0

    TELLEZ CORA M

    • Director
    		 472,174 2017-05-30 0

    GEORGE MICHAEL W

    • Director
    		 289,830 2017-05-15 0

    MARKVICKA TAUNIA

    • Director
    		 260,671 2017-05-15 0

    PFAFFLE ANTONY CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2017-02-07 0

    ABRAMS JUDITH R CHIEF MEDICAL OFFICER

    • Officer
    		 0 2017-02-01 0

    MILBY RANDY CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 403,269 2016-08-10 0

    DUFFY MATTHEW

    • Director
    		 28,571 2016-06-03 0

    O'GRADY HARRY CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2014-07-21 0

    COHEN RICHARD CHIEF FINANCIAL OFFICDER

    • Officer
    • Director
    		 0 2013-03-20 0

    PHARMABIO DEVELOPMENT INC

    • 10% Owner
    		 778,563 2012-04-12 0

    LENZ BRIAN SEE REMARKS

    • Officer
    		 0 2012-03-20 0

    HOFER TIMOTHY M

    • Director
    		 0 2012-01-06 0

    LEFKOWITZ JAMES

    • Director
    		 40,272 2011-12-15 0

    KLAUSNER MARK A. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2011-03-01 0

    BASTANI BAMI

    • Director
    		 0 2011-01-14 0

    HOUSER MARK T. CHIEF MEDICAL OFFICER

    • Officer
    		 52,832 2010-11-26 0

    HOUGHTON JOHN C. PRESIDENT AND CEO

    • Officer
    • Director
    		 19,728 2010-08-18 0

    ELLISON RUSSELL H

    • Director
    		 260,000 2010-03-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CORMEDIX INC CRMD 2023-03-24 22:15:03 UTC 4.0142 0.8058 350000
    CORMEDIX INC CRMD 2023-03-24 21:45:03 UTC 4.0051 0.8149 350000
    CORMEDIX INC CRMD 2023-03-24 21:15:03 UTC 4.0051 0.8149 350000
    CORMEDIX INC CRMD 2023-03-24 20:45:03 UTC 4.0037 0.8163 350000
    CORMEDIX INC CRMD 2023-03-24 20:15:04 UTC 4.0037 0.8163 350000
    CORMEDIX INC CRMD 2023-03-24 19:45:03 UTC 4.0037 0.8163 350000
    CORMEDIX INC CRMD 2023-03-24 19:15:04 UTC 4.0037 0.8163 350000
    CORMEDIX INC CRMD 2023-03-24 18:45:04 UTC 3.9923 0.8277 400000
    CORMEDIX INC CRMD 2023-03-24 18:15:03 UTC 3.9923 0.8277 400000
    CORMEDIX INC CRMD 2023-03-24 17:45:03 UTC 3.9923 0.8277 400000
    CORMEDIX INC CRMD 2023-03-24 17:15:03 UTC 3.9923 0.8277 400000
    CORMEDIX INC CRMD 2023-03-24 16:45:03 UTC 3.9577 0.8623 400000
    CORMEDIX INC CRMD 2023-03-24 16:15:03 UTC 3.9577 0.8623 350000
    CORMEDIX INC CRMD 2023-03-24 15:45:03 UTC 3.9577 0.8623 400000
    CORMEDIX INC CRMD 2023-03-24 15:15:03 UTC 3.9577 0.8623 400000
    CORMEDIX INC CRMD 2023-03-24 14:45:03 UTC 3.9577 0.8623 1000000
    CORMEDIX INC CRMD 2023-03-24 14:15:03 UTC 3.9577 0.8623 1000000
    CORMEDIX INC CRMD 2023-03-24 13:45:03 UTC 3.7776 0.7924 1000000
    CORMEDIX INC CRMD 2023-03-24 13:15:04 UTC 3.7776 0.7924 1000000
    CORMEDIX INC CRMD 2023-03-24 12:45:03 UTC 3.7776 0.7924 1000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund CRMD -11943.0 shares, $-36665.01 2022-10-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments